Cargando…

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey

The Gaucher Outcome Survey (GOS) is an international disease-specific registry established in 2010 for patients with a confirmed diagnosis of Gaucher disease (GD), regardless of GD type or treatment status. Historically, there has been a limited understanding of type 3 GD (GD3) and its natural histo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwartz, Ida Vanessa D., Göker-Alpan, Özlem, Kishnani, Priya S., Zimran, Ari, Renault, Lydie, Panahloo, Zoya, Deegan, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758841/ https://www.ncbi.nlm.nih.gov/pubmed/29326879 http://dx.doi.org/10.1016/j.ymgmr.2017.10.011

Ejemplares similares

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Optimal therapy in Gaucher disease
por: Goker-Alpan, Ozlem
Publicado: (2010)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
por: Hughes, Derralynn A., et al.
Publicado: (2023)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials
por: Elstein, Deborah, et al.
Publicado: (2022)

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019)

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
por: Elstein, Deborah, et al.
Publicado: (2009)

Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases
por: Ivanova, Margarita M., et al.
Publicado: (2019)

Biofabrication of an in-vitro bone model for Gaucher disease
por: Banerjee, Dishary, et al.
Publicado: (2023)

Dental profile of patients with Gaucher disease
por: Fischman, Stuart L, et al.
Publicado: (2003)

Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease
por: Limgala, Renuka P., et al.
Publicado: (2020)

TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease
por: Ivanova, Margarita, et al.
Publicado: (2021)

Simultaneous Bilateral Femoral Osteonecrosis in Gaucher Disease
por: Cohen, Daniel, et al.
Publicado: (2023)

Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
por: Mistry, Pramod, et al.
Publicado: (2020)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease
por: Limgala, Renuka Pudi, et al.
Publicado: (2016)

Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2022)

Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2021)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

COVID-19 patient impact: A survey of the Gaucher community involving patients, caregivers and family members based in the US to determine impact of the pandemic
por: Ryan, Emory, et al.
Publicado: (2021)

Assessment of cellular cobalamin metabolism in Gaucher disease
por: Basgalupp, Suelen Porto, et al.
Publicado: (2020)

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY
por: Mistry, Pramod, et al.
Publicado: (2023)

The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
por: Mistry, Pramod K., et al.
Publicado: (2023)

The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients
por: Deegan, Patrick, et al.
Publicado: (2021)

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
por: Revel-Vilk, Shoshana, et al.
Publicado: (2020)

Imiglucerase in the treatment of Gaucher disease: a history and perspective
por: Deegan, Patrick B, et al.
Publicado: (2012)

Gaucher Cells or Pseudo-Gaucher Cells: That’s the Question
por: Gören Şahin, Deniz, et al.
Publicado: (2014)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2018)

GBA1 variants in Brazilian Gaucher disease patients
por: Basgalupp, Suelen Porto, et al.
Publicado: (2023)

Assessment of quality of life in Gaucher disease: A methodological approach
por: Zizemer, Vitória S., et al.
Publicado: (2020)

Breastfeeding in patients with Gaucher disease: Is taliglucerase alfa safe?
por: Paskulin, Livia, et al.
Publicado: (2019)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Gaucher’s Disease
Publicado: (1916)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dhu82jil58n3f8bpta5bd4hkop